Urinary excretion of prostacyclin and thromboxane degradation products in patients with ovarian malignancy: effect of cytostatic treatment

A Aitokallio-Tallberg, L Viinikka, O Ylikorkala
British journal of cancer · 1989 · doi:10.1038/bjc.1989.360 · PMID:2803956 · PMC2247297
other OA: gold public-domain-us
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-12 ⓘ

Ovarian cancer patients showed elevated urinary prostacyclin and thromboxane products, which initially rose then fell during cytostatic treatment before tending to normalize after multiple courses.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-12 · read from full text ⓘ

This paper investigated urinary excretion of prostacyclin (6-keto-PGF1α and 2,3-dinor-6-keto-PGF1α) and thromboxane A2 degradation products (thromboxane B2 and 2,3-dinor-TxB2) in six patients with ovarian malignancy before, during, and after combined chemotherapy with cisplatin, 4′-epi-adriamycin, and cyclophosphamide, with repeated courses in some patients. Before the first cytostatic infusion, prostanoid excretion was on average 4.4–5.8 times higher than in a comparison group of patients with ovarian endometriosis (n = 19). After chemotherapy, urinary prostanoid excretion rose 50–120% during the first 9 hours post-infusion but then fell 25–45% below baseline over the next 10 hours and stayed low for at least 2 weeks, with subsequent normalization tendency after 2–4 courses. The study involved very small ovarian-cancer sampling (n=6) and reports limited mechanistic interpretation beyond the observed suppression by cytostatics. This paper is centrally about ovarian malignancy and cytostatic effects on prostanoid metabolites, but it explicitly contrasts urinary prostanoids with ovarian endometriosis and therefore is relevant to endometriosis via the reported endometriosis comparison.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

We studied the effect of ovarian cancer and its chemotherapy on the urinary excretion of prostacyclin (PGI2) and thromboxane A2 (TxA2) hydration and metabolic products. In six patients we measured 6-keto-PGF1 alpha and 2,3-dinor-6-keto-PGF1 alpha (PGI2 products) and thromboxane B2 (TxB2) and 2,3-dinor-TxB2 (TxA2 products) by HPLC followed by radioimmunoassay before, during and after the combined infusion of cisplatin, 4'epi-adriamycin and cyclophosphamide. Before the first cytostatic infusion, the urinary excretion of prostanoids was on average 4.4-5.8 times higher than in patients with ovarian endometriosis (n = 19). The infusion of cytostatics led to a 50-120% rise in the excretion of prostanoids during the first post-infusion 9 hours, but in the subsequent 10 hours their output was 25-45% below the initial value and remained low for at least 2 weeks. Following repetitive courses of cytostatics (2-4 per patient), prostanoid excretion tended to normalise. These data suggest that ovarian cancer is associated with increased production of PGI2 and TxA2, and that cytostatics suppress this production. This may be of biological significance in tumour behaviour and in the effect of cytostatics.
Full text 2,040 characters · extracted from oa-doi-fallback · click to expand
Abstract We studied the effect of ovarian cancer and its chemotherapy on the urinary excretion of prostacyclin (PGI2) and thromboxane A2 (TxA2) hydration and metabolic products. In six patients we measured 6-keto-PGF1 alpha and 2,3-dinor-6-keto-PGF1 alpha (PGI2 products) and thromboxane B2 (TxB2) and 2,3-dinor-TxB2 (TxA2 products) by HPLC followed by radioimmunoassay before, during and after the combined infusion of cisplatin, 4'epi-adriamycin and cyclophosphamide. Before the first cytostatic infusion, the urinary excretion of prostanoids was on average 4.4-5.8 times higher than in patients with ovarian endometriosis (n = 19). The infusion of cytostatics led to a 50-120% rise in the excretion of prostanoids during the first post-infusion 9 hours, but in the subsequent 10 hours their output was 25-45% below the initial value and remained low for at least 2 weeks. Following repetitive courses of cytostatics (2-4 per patient), prostanoid excretion tended to normalise. These data suggest that ovarian cancer is associated with increased production of PGI2 and TxA2, and that cytostatics suppress this production. This may be of biological significance in tumour behaviour and in the effect of cytostatics. This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 24 print issues and online access 251,40 € per year only 10,48 € per issue Buy this article - Purchase on SpringerLink - Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout Similar content being viewed by others Author information Authors and Affiliations Rights and permissions About this article Cite this article Aitokallio-Tallberg, A., Viinikka, L. & Ylikorkala, O. Urinary excretion of prostacyclin and thromboxane degradation products in patients with ovarian malignancy: effect of cytostatic treatment. Br J Cancer 60, 785–788 (1989). https://doi.org/10.1038/bjc.1989.360 Issue date: DOI: https://doi.org/10.1038/bjc.1989.360

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

6-Ketoprostaglandin F1 alpha Adenocarcinoma Antineoplastic Combined Chemotherapy Protocols Ovarian Neoplasms Thromboxane B2 6-Ketoprostaglandin F1 alpha 6-Ketoprostaglandin F1 alpha Adenocarcinoma Adenocarcinoma Adolescent Adult Aged Antineoplastic Combined Chemotherapy Protocols Cisplatin Cisplatin Cyclophosphamide Cyclophosphamide Cystadenocarcinoma Cystadenocarcinoma Cystadenocarcinoma

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-20T06:14:18.781669+00:00
pubmed
last seen: 2026-05-13T22:09:10.744835+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine